company background image
BIIB

Biogen NasdaqGS:BIIB Stock Report

Last Price

US$255.02

Market Cap

US$36.9b

7D

0.7%

1Y

30.3%

Updated

25 Sep, 2023

Data

Company Financials +

BIIB Stock Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

BIIB fundamental analysis
Snowflake Score
Valuation6/6
Future Growth1/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Biogen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biogen
Historical stock prices
Current Share PriceUS$255.02
52 Week HighUS$319.76
52 Week LowUS$194.63
Beta0.13
1 Month Change-3.56%
3 Month Change-9.87%
1 Year Change30.28%
3 Year Change-9.58%
5 Year Change-27.67%
Change since IPO8,170.92%

Recent News & Updates

Recent updates

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16
Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Jun 28
Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued

Apr 14
An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued

Is Biogen (NASDAQ:BIIB) A Risky Investment?

Mar 27
Is Biogen (NASDAQ:BIIB) A Risky Investment?

Calculating The Intrinsic Value Of Biogen Inc. (NASDAQ:BIIB)

Jan 14
Calculating The Intrinsic Value Of Biogen Inc. (NASDAQ:BIIB)

Is Biogen (NASDAQ:BIIB) A Risky Investment?

Dec 25
Is Biogen (NASDAQ:BIIB) A Risky Investment?

Biogen upgraded to buy at Stifel on lecanemab Alzheimer's treatment

Oct 13

Biogen Inc. (NASDAQ:BIIB) Shares Could Be 44% Below Their Intrinsic Value Estimate

Oct 07
Biogen Inc. (NASDAQ:BIIB) Shares Could Be 44% Below Their Intrinsic Value Estimate

Teamwork Pays: Biogen, Eisai Announce Positive Results For Alzheimer's Drug

Sep 29

Biogen sells 271K square foot Cambridge, Mass. property for $592M

Sep 23

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Sep 19
Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Biogen: Forecasting Suggests Buying At Historical Lows Advisable

Aug 29

Lecanemab And Biogen's Path To Growth

Aug 22

Shareholder Returns

BIIBUS BiotechsUS Market
7D0.7%-1.5%-2.7%
1Y30.3%11.8%16.8%

Return vs Industry: BIIB exceeded the US Biotechs industry which returned 11.8% over the past year.

Return vs Market: BIIB exceeded the US Market which returned 16.8% over the past year.

Price Volatility

Is BIIB's price volatile compared to industry and market?
BIIB volatility
BIIB Average Weekly Movement2.3%
Biotechs Industry Average Movement9.1%
Market Average Movement5.5%
10% most volatile stocks in US Market14.2%
10% least volatile stocks in US Market2.5%

Stable Share Price: BIIB is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: BIIB's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19788,725Chris Viehbacherhttps://www.biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

Biogen Inc. Fundamentals Summary

How do Biogen's earnings and revenue compare to its market cap?
BIIB fundamental statistics
Market CapUS$36.93b
Earnings (TTM)US$2.66b
Revenue (TTM)US$9.97b

13.9x

P/E Ratio

3.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIIB income statement (TTM)
RevenueUS$9.97b
Cost of RevenueUS$2.37b
Gross ProfitUS$7.60b
Other ExpensesUS$4.94b
EarningsUS$2.66b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)18.40
Gross Margin76.23%
Net Profit Margin26.72%
Debt/Equity Ratio43.5%

How did BIIB perform over the long term?

See historical performance and comparison